---
title: "Ardelyx, Inc. (ARDX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ARDX.US.md"
symbol: "ARDX.US"
name: "Ardelyx, Inc."
industry: "Biotechnology"
datetime: "2026-05-02T09:04:47.687Z"
locales:
  - [en](https://longbridge.com/en/quote/ARDX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ARDX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ARDX.US.md)
---

# Ardelyx, Inc. (ARDX.US)

## Company Overview

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.ardelyx.com](https://www.ardelyx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-02T04:30:18.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 110 / 387 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 18.24% |  |
| Net Profit YoY | -7.99% |  |
| P/B Ratio | 11.35 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1687302297.76 |  |
| Revenue | 427679000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -39.46% | E |
| Profit Margin | -13.58% | D |
| Gross Margin | 94.91% | A |
| Revenue YoY | 18.24% | B |
| Net Profit YoY | -7.99% | D |
| Total Assets YoY | 22.99% | A |
| Net Assets YoY | 2.02% | C |
| Cash Flow Margin | 62.46% | C |
| OCF YoY | 18.24% | B |
| Turnover | 0.94 | A |
| Gearing Ratio | 70.54% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ardelyx, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "18.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-7.99%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "11.35",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1687302297.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "427679000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-39.46%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-13.58%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "94.91%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "18.24%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-7.99%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "22.99%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.02%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "62.46%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "18.24%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.94",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "70.54%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -29.06 | 510/387 | - | - | - |
| PB | 11.35 | 393/387 | 10.61 | 8.98 | 7.14 |
| PS (TTM) | 3.95 | 88/387 | 3.90 | 3.53 | 2.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 02 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 03 | OpGen (OPGN.US) | B | A | A | A | C | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Argenx (ARGX.US) | A | A | B | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-01T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 90% |
| Overweight | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.88 |
| Highest Target | 19.00 |
| Lowest Target | 13.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ARDX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ARDX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ARDX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ARDX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**